Urothelial Carcinoma | Norton Healthcare

Indication: Urothelial Carcinoma

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Advanced or metastatic

Sub-indication: Advanced or metastatic urothelial carcinoma

Line of Therapy: Cohort 1: Must have received prior chemotherapy which included a platinum agent. Cohort 2: Must have been ineligible for platinum-based chemotherapy.

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: Mirati Therapeutics, Inc

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.